Use of humic acids in the treatment of genitourinary diseases

Abstract

Currently, diseases of the urogenital system has acquired medical and social importance. This is primarily due to the significant prevalence of this group of diseases in the structure of general morbidity, disability, and mortality and their frequent recurrence and effect on the somatic and emotional state of the patient. In addition to socio-demographic problems, urogenital disorders have significant economic consequences. The total annual costs of treating uronephrological diseases, including accompanying therapy, are estimated at 40 billion US dollars. However, according to expert forecasts, by 2030, the prevalence of this group of diseases is expected to increase by 25%, as well as direct costs of disease treatment and indirect costs associated with partial or total disability due to disease development and premature death.

Thus, searching for and developing new drugs for the treatment of diseases of the urogenital organs are crucial. Chemical compounds, potentially significant in this aspect, can be obtained by organic synthesis and isolated from natural sources. Thus, exploring the potential of natural compounds that have high biological activity and favorable safety profile is a significant reason to realize and address this issue. An interesting but understudied groups of natural compounds of plant origin are humic substances. Recent preclinical studies have shown that they are able to exert antitumor, nephroprotective, and diuretic effects and exhibit antibacterial and antifungal properties.

This review aimed to summarize and systematize currently available information on the known pharmacological effects and possible mechanisms of action of humic acids and the prospects for their use in the treatment and prevention of genitourinary diseases.

Keywords

humus acids / humic acid / fulvic acid / hymatomelanic acid / antimicrobial properties / antitumor properties / diseases of the genitourinary system

References

[1] Dirks J, Remuzzi G, Horton S, et al. Diseases of the kidney and the urinary system. Jamison DT, Breman JG, Measham AR, et al., editors. In: Disease control priorities in developing countries. 2nd edition. Washington: The International Bank for Reconstruction and Development; 2006.

[2] Dirks J., Remuzzi G., Horton S., et al. Diseases of the kidney and the urinary system. Jamison D.T., Breman J.G., Measham A.R., et al., editors. In: Disease control priorities in developing countries. 2nd edition. Washington: The International Bank for Reconstruction and Development, 2006.

[3] Stamm WE, Norrby SR. Urinary tract infections: disease panorama and challenges. J Infect Dis. 2001;183 Suppl. 1:S1–S4. doi: 10.1086/318850

[4] Stamm W.E., Norrby S.R. Urinary tract infections: disease panorama and challenges // J Infect Dis. 2001. Vol. 183, Suppl. 1. P. S1–S4. doi: 10.1086/318850

[5] Bergeron-Boucher MP, Aburto JM, van Raalte A. Diversification in causes of death in low-mortality countries: emerging patterns and implications. BMJ Glob Health. 2020;5(7):e002414. doi: 10.1136/bmjgh-2020-002414

[6] Bergeron-Boucher M.P., Aburto J.M., van Raalte A. Diversification in causes of death in low-mortality countries: emerging patterns and implications // BMJ Glob Health. 2020. Vol. 5, N 7. P. e002414. doi: 10.1136/bmjgh-2020-002414

[7] World Health Organization. The Global Burden of Disease: 2004 Update. Geneva: World Health Organization; 2004. 146 p.

[8] World Health Organization. The Global Burden of Disease: 2004 Update. Geneva: World Health Organization, 2004. 146 p.

[9] Zhu C, Wang DQ, Zi H, et al. Epidemiological trends of urinary tract infections, urolithiasis and benign prostatic hyperplasia in 203 countries and territories from 1990 to 2019. Mil Med Res. 2021;8(1):64. doi: 10.1186/s40779-021-00359-8

[10] Zhu C., Wang D.Q., Zi H., et al. Epidemiological trends of urinary tract infections, urolithiasis and benign prostatic hyperplasia in 203 countries and territories from 1990 to 2019 // Mil Med Res. 2021. Vol. 8, N 1. P. 64. doi: 10.1186/s40779-021-00359-8

[11] Zi H, He SH, Leng XY, et al. Global, regional, and national burden of kidney, bladder, and prostate cancers and their attributable risk factors, 1990–2019. Mil Med Res. 2021;8(1):60. doi: 10.1186/s40779-021-00354-z

[12] Zi H., He S.H., Leng X.Y., et al. Global, regional, and national burden of kidney, bladder, and prostate cancers and their attributable risk factors, 1990–2019 // Mil Med Res. 2021. Vol. 8, N 1. P. 60. doi: 10.1186/s40779-021-00354-z

[13] Luyckx VA, Tonelli M, Stanifer JW. The global burden of kidney disease and the sustainable development goals. Bull World Health Organ. 2018;96(6):414D–422D. doi: 10.2471/BLT.17.206441

[14] Luyckx V.A., Tonelli M., Stanifer J.W. The global burden of kidney disease and the sustainable development goals // Bull World Health Organ. 2018. Vol. 96, N 6. P. 414–422D. doi: 10.2471/BLT.17.206441

[15] Kim MM, Harvey J, Gusev A, et al. A scoping review of the economic burden of non-cancerous genitourinary conditions. Urology. 2022;166:29–38. doi: 10.1016/j.urology.2021.10.008

[16] Kim M.M., Harvey J., Gusev A., et al. A scoping review of the economic burden of non-cancerous genitourinary conditions // Urology. 2022. Vol. 166. P. 29–38. doi: 10.1016/j.urology.2021.10.008

[17] Litwin MS, Saigal CS, editors. Urologic diseases in America. Washington: US Government Printing Office; 2012.

[18] Litwin M.S., Saigal C.S., editors. Urologic diseases in America. Washington: US Government Printing Office, 2012.

[19] Orlov DS. Humic substances in the biosphere. Sorosovskij obrazovatel'nyj zhurnal. 1997;3(2):56–63. (In Russ).

[20] Орлов Д.С. Гуминовые вещества в биосфере // Соросовский образовательный журнал. 1997. Т. 3, № 2. С. 56–63.

[21] Perminova IV. Analysis, classification and prediction of the properties of humic acids [dissertation]. Moscow; 2000. Available from: http://mgumus.chem.msu.ru/publication/01-titul.pdf (In Russ). EDN: QDGUCR

[22] Перминова И.В. Анализ, классификация и прогноз свойств гумусовых кислот: дис. … д-ра хим. наук. Москва, 2000. Режим доступа: http://mgumus.chem.msu.ru/publication/01-titul.pdf Дата обращения: 01.03.2024. EDN: QDGUCR

[23] Avvakumova NP. Composition and biological properties of humic acids in peloids: fundamental and applied aspects [dissertation]. Samara; 2003. Available from: http://dlib.rsl.ru/rsl01002000000/rsl01002606000/rsl01002606904/rsl01002606904.pdf (In Russ). EDN: QDWDPZ

[24] Аввакумова Н.П. Состав и биологические свойства гумусовых кислот пелоидов: фундаментальные и прикладные аспекты: дис. … д-ра биол. наук. Самара, 2003. Режим доступа: http://dlib.rsl.ru/rsl01002000000/rsl01002606000/rsl01002606904/rsl01002606904.pdf Дата обращения: 01.03.2024 EDN: QDWDPZ

[25] Danchenko NN. Functional composition of humic acids: definition and relationship to reactivity [dissertation]. Moscow; 1997. Available from: http://www.mgumus.chem.msu.ru/researches/Avtoreferaty/danchenko-diss.pdf (In Russ).

[26] Данченко Н.Н. Функциональный состав гумусовых кислот: определение и взаимосвязь с реакционной способностью: дис. … канд. хим. наук. Москва, 1997. Режим доступа: http://www.mgumus.chem.msu.ru/researches/Avtoreferaty/danchenko-diss.pdf Дата обращения: 01.03.2024

[27] Aleksandrova LN. Soil organic matter and its transformation processes. Leningrad: Nauka. Leningradskoe otdelenie; 1980. (In Russ).

[28] Александрова Л.Н. Органическое вещество почвы и процессы ее трансформации. Ленинград: Наука. Ленинградское отделение, 1980.

[29] Kononova MM. The problem of soil humus and modern tasks of its study. Moscow: Izdatel’stvo Akademii nauk SSSR; 1951. (In Russ). EDN: ZBEAOT

[30] Кононова М.М. Проблема почвенного гумуса и современные задачи его изучения. Москва: Издательство Академии наук СССР, 1951. EDN: ZBEAOT

[31] Lishtvan II, Kruglickij NN, Tretinnik VU. Physicochemical mechanics of humic substances. Minsk: Nauka i tekhnika; 1976. (In Russ).

[32] Лиштван И.И., Круглицкий Н.Н., Третинник В.Ю. Физико-химическая механика гуминовых веществ. Минск: Наука и техника, 1976.

[33] Orlov DS. Humic acids of soils and the general theory of humification. Moscow: Izdatel’stvo MGU; 1990. (In Russ).

[34] Орлов Д.С. Гумусовые кислоты почв и общая теория гумификации. Москва: Издательство МГУ, 1990.

[35] Zhdanova AV. Study of structural components and physicochemical properties of humic substances of low-mineralized silt sulfide muds as a source of antioxidant drugs [dissertation]. Samara; 2011. Available from: http://dlib.rsl.ru/rsl01004000000/rsl01004846000/rsl01004846945/rsl01004846945.pdf (In Russ). EDN: QFJRPH

[36] Жданова А.В. Изучение структурных компонентов и физико-химических свойств гуминовых веществ низкоминерализованных иловых сульфидных грязей как источника антиоксидантных лекарственных средств: дис. … канд. фарм. наук. Самара, 2011. Режим доступа: http://dlib.rsl.ru/rsl01004000000/rsl01004846000/rsl01004846945/rsl01004846945.pdf. Дата обращения: 01.04.2023 EDN: QFJRPH

[37] Avvakumova NP, Glubokova MN, Zhdanova AV, et al. Optimization of humic acids dialysis. Izvestiya Samarskogo nauchnogo centra RAN. 2009;11(1-6):1256–1258. EDN: MCLCFH

[38] Аввакумова Н.П., Глубокова М.Н., Жданова А.В., и др. Оптимизация диализа гуминовых кислот // Известия Самарского научного центра РАН. 2009. Т. 11, № 1-6. С. 1256–1258. EDN: MCLCFH

[39] Murbach TS, Glávits R, Endres JR, et al. A toxicological evaluation of a fulvic and humic acids preparation. Toxicol Rep. 2020;7: 1242–1254. doi: 10.1016/j.toxrep.2020.08.030

[40] Murbach T.S., Glávits R., Endres J.R., et al. A toxicological evaluation of a fulvic and humic acids preparation // Toxicol Rep. 2020. Vol. 7. P. 1242–1254. doi: 10.1016/j.toxrep.2020.08.030

[41] Gandy JJ, Meeding JP, Snyman JR, et al. Phase 1 clinical study of the acute and subacute safety and proof-of-concept efficacy of carbohydrate-derived fulvic acid. Clin Pharmacol. 2012;4:7–11. doi: 10.2147/CPAA.S25784

[42] Gandy J.J., Meeding J.P., Snyman J.R., van Rensburg C.E. Phase 1 clinical study of the acute and subacute safety and proof-of-concept efficacy of carbohydrate-derived fulvic acid // Clin Pharmacol. 2012. Vol. 4. P. 7–11. doi: 10.2147/CPAA.S25784

[43] Gnananath K, Nataraj KS, Rao BG, et al. Exploration of fulvic acid as a functional excipient in line with the regulatory requirement. Environ Res. 2020;187:109642. doi: 10.1016/j.envres.2020.109642

[44] Gnananath K., Nataraj K.S., Rao B.G., et al. Exploration of fulvic acid as a functional excipient in line with the regulatory requirement // Environ Res. 2020. Vol. 187. P. 109642. doi: 10.1016/j.envres.2020.109642

[45] Dai C, Xiao X, Yuan Y, et al. A comprehensive toxicological assessment of fulvic acid. Evid Based Complement Alternat Med. 2020;2020:8899244. doi: 10.1155/2020/8899244

[46] Dai C., Xiao X., Yuan Y., et al. A comprehensive toxicological assessment of fulvic acid // Evid Based Complement Alternat Med. 2020. Vol. 2020. P. 8899244. doi: 10.1155/2020/8899244

[47] Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13(5):269–284. doi: 10.1038/nrmicro3432

[48] Flores-Mireles A.L., Walker J.N., Caparon M., Hultgren S.J. Urinary tract infections: epidemiology, mechanisms of infection and treatment options // Nat Rev Microbiol. 2015. Vol. 13, N 5. P. 269–284. doi: 10.1038/nrmicro3432

[49] Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. Am J Med. 2002;113 Suppl. 1A:14S–19S. doi: 10.1016/s0002-9343(02)01055-0

[50] Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens // Am J Med. 2002. Vol. 113, Suppl. 1A. P. 14S–19S. doi: 10.1016/s0002-9343(02)01055-0

[51] Paul R. State of the globe: rising antimicrobial resistance of pathogens in urinary tract infection. J Glob Infect Dis. 2018;10(3): 117–118. doi: 10.4103/jgid.jgid_104_17

[52] Paul R. State of the globe: rising antimicrobial resistance of pathogens in urinary tract infection // Journal of Global Infectious Diseases. 2018. Vol. 10, N 3. P. 117. doi: 10.4103/jgid.jgid_104_17

[53] Li X, Fan H, Zi H, et al. Global and regional burden of bacterial antimicrobial resistance in urinary tract infections in 2019. J Clin Med. 2022;11(10):2817. doi: 10.3390/jcm11102817

[54] Li X., Fan H., Zi H., et al. Global and regional burden of bacterial antimicrobial resistance in urinary tract infections in 2019 // J Clin Med. 2022. Vol. 11, N 10. P. 2817. doi: 10.3390/jcm11102817

[55] Tadigieva NZ, Coj EG, Turovskaya SI. Antibacterial activity of humic preparation from medicinal peat mud Dzhelal. Biologicheskie nauki. 1991;(10):109–113. (In Russ).

[56] Тадигиева Н.З., Цой Е.Г., Туровская С.И. Антибактериальная активность гуминового препарата из лечебной торфяной грязи Джелал // Биологические науки. 1991. № 10. С. 109–113.

[57] Krasnikova ES, Pavlenko VV, Matrenov IS. Study of bactericidal and fungicidal activity of the supplementary feed based on humic acids. Uchenye zapiski Kazanskoj gosudarstvennoj akademii veterinarnoj mediciny im. N.E Baumana. 2019;239(3):158–160. EDN: CDNJRW doi: 10.31588/2413-4201-1883-239-3-158-160

[58] Красникова Е.С., Павленко В.В., Матренов И.С. Изучение бактерицидной и фунгицидной активности кормовой добавки на основе гуминовых кислот // Ученые записки Казанской государственной академии ветеринарной медицины им. Н.Э. Баумана. 2019. Т. 239, № 3. С. 158–160. EDN: CDNJRW doi: 10.31588/2413-4201-1883-239-3-158-160

[59] Verrillo M, Salzano M, Meo VD, et al. Antibacterial and antioxidant properties of humic substances from composted agricultural biomasses. Chemical and Biological Technologies in Agriculture. 2022;9(1):28. doi: 10.1186/s40538-022-00291-6

[60] Verrillo M., Salzano M., Meo V.D., et al. Antibacterial and antioxidant properties of humic substances from composted agricultural biomasses // Chemical and Biological Technologies in Agriculture. 2022. Vol. 9, N 1. P. 28. doi: 10.1186/s40538-022-00291-6

[61] Patent US 9265744B2. Leivers SW, Warn P. Fulvic acid and antibiotic combination for the inhibition or treatment of multi-drug resistant bacteria. United States, 2016. Available from: https://patents.google.com/patent/EP2822551B1/es

[62] Patent US 9265744B2. Leivers S.W., Warn P. Fulvic acid and antibiotic combination for the inhibition or treatment of multi-drug resistant bacteria. United States, 2016. Режим доступа: https://patents.google.com/patent/EP2822551B1/es

[63] Zhao Y, Paderu P, Delmas G, et al. Carbohydrate-derived fulvic acid is a highly promising topical agent to enhance healing of wounds infected with drug-resistant pathogens. J Trauma Acute Care Surg. 2015;79(4 Suppl. 2):S121–S129. doi: 10.1097/TA.0000000000000737

[64] Zhao Y., Paderu P., Delmas G., et al. Carbohydrate-derived fulvic acid is a highly promising topical agent to enhance healing of wounds infected with drug-resistant pathogens // J Trauma Acute Care Surg. 2015. Vol. 79(4 Suppl. 2). P. S121–S129. doi: 10.1097/TA.0000000000000737

[65] Gorovaya AI, Orlov DS, Shcherbenko OV. Humic substances. Construction, functions, mechanism of action, protective properties, ecological role. Kiev: Naukova dumka; 1995. (In Russ).

[66] Горовая А.И., Орлов Д.С., Щербенко О.В. Гуминовые вещества. Конструкция, функции, механизм действия, защитные свойства, экологическая роль. Киев: Наукова думка, 1995.

[67] Popov AI, Zelenkov VN, Teplyakova TV. Biological activity and biochemistry of humic substances. Part 2. Medico-biological aspect (a review). Vestnik Rossijskoj Akademii estestvennyh nauk. 2016;(5):9–16.

[68] Попов А.И., Зеленков В.Н., Теплякова Т.В. Биологическая активность и биохимия гуминовых веществ. Часть 2. Медико-биологический аспект (обзор литературы) // Вестник Российской Академии естественных наук. 2016. № 5. С. 9–16.

[69] Man D, Pisarek I, Braczkowski M, et al. The impact of humic and fulvic acids on the dynamic properties of liposome membranes: the ESR method. J Liposome Res. 2014;24(2):106–112. doi: 10.3109/08982104.2013.839998

[70] Man D., Pisarek I., Braczkowski M., et al. The impact of humic and fulvic acids on the dynamic properties of liposome membranes: the ESR method // J Liposome Res. 2014. Vol. 24, N 2. P. 106–112. doi: 10.3109/08982104.2013.839998

[71] de Wit H. Proton and metal ion binding to humic substances. Wageningen: Wageningen University and Research; 1992.

[72] de Wit H. Proton and metal ion binding to humic substances. Wageningen: Wageningen University and Research, 1992.

[73] de Melo BA, Motta FL, Santana MH. Humic acids: structural properties and multiple functionalities for novel technological developments. Mater Sci Eng C Mater Biol Appl. 2016;62:967–974. doi: 10.1016/j.msec.2015.12.001

[74] de Melo B.A., Motta F.L., Santana M.H. Humic acids: structural properties and multiple functionalities for novel technological developments // Mater Sci Eng C Mater Biol Appl. 2016. Vol. 62. P. 967–974. doi: 10.1016/j.msec.2015.12.001

[75] Mikhnevich TA, Vyatkina Turkova AV, Grigorenko VG, et al. Inhibition of class A β-lactamase (TEM-1) by narrow fractions of humic substances. ACS omega. 2021;6(37):23873–23883. doi: 10.1021/acsomega.1c02841

[76] Mikhnevich T.A., Vyatkina A.V., Grigorenko V.G., et al. Inhibition of class A β-lactamase (TEM-1) by narrow fractions of humic substances // ACS omega. 2021. Vol. 6, N 37. P. 23873–23883. doi: 10.1021/acsomega.1c02841

[77] Kravtsova D, Cherkasova T, Rubtsova M, et al. Humic substances potentiate inhibitory activity of sulbactam with respect to β-lactamase TEM-1. In: Perminova I, editors. Fifth International Conference of CIS IHSS on Humic Innovative Technologies «Humic substances and living systems» (HIT-2019); 2019 October 19–23; Moscow, Russia. Moscow: Desktop publishing by Alexander Polyakov; 2019. P. 105. doi: 10.36291/HIT.2019.kravtsova.093

[78] Kravtsova D., Cherkasova T., Rubtsova M., et al. Humic substances potentiate inhibitory activity of sulbactam with respect to β-lactamase TEM-1. In: Perminova I., editors. Fifth International Conference of CIS IHSS on Humic Innovative Technologies «Humic substances and living systems» (HIT-2019); 2019 October 19–23; Moscow, Russia. Moscow: Desktop publishing by Alexander Polyakov; 2019. P. 105. doi: 10.36291/HIT.2019.kravtsova.093

[79] Dias V. Candida species in the urinary tract: is it a fungal infection or not? Future Microbiol. 2020;15:81–83. doi: 10.2217/fmb-2019-0262

[80] Dias V. Candida species in the urinary tract: is it a fungal infection or not? // Future microbiology. 2020. Vol. 15. P. 81–83. doi: 10.2217/fmb-2019-0262

[81] Sobel JD, Fisher JF, Kauffman CA, Newman CA. Candida urinary tract infections-epidemiology. Clin Infect Dis. 2011;52 Suppl. 6: S433–S436. doi: 10.1093/cid/cir109

[82] Sobel J.D., Fisher J.F., Kauffman C.A., Newman C.A. Candida urinary tract infections — epidemiology // Clin Infect Dis. 2011. Vol. 52, Suppl. 6. P. S433–S436. doi: 10.1093/cid/cir109

[83] Carvalho M, Guimarães CM, Mayer JR Jr, et al. Hospital-associated funguria: analysis of risk factors, clinical presentation and outcome. Braz J Infect Dis. 2001;5(6):313–318. doi: 10.1590/s1413-86702001000600004

[84] Carvalho M., Guimarães C.M., Mayer J.R. Jr, et al. Hospital-associated funguria: analysis of risk factors, clinical presentation and outcome // Braz J Infect Dis. 2001. Vol. 5, N 6. P. 313–318. doi: 10.1590/s1413-86702001000600004

[85] Sobel JD, Vazquez JA. Fungal infections of the urinary tract. World J Urol. 1999;17(6):410–414. doi: 10.1007/s003450050167

[86] Sobel J.D., Vazquez J.A. Fungal infections of the urinary tract // World J Urol. 1999. Vol. 17, N 6. P. 410–414. doi: 10.1007/s003450050167

[87] Rafal’skij VV. Clinical significance and therapy of candiduria. Clinical Microbiology and Antimicrobial Chemotherapy. 2001;3(1): 22–27. (In Russ). EDN: VXFOSP

[88] Рафальский В.В. Клиническое значение и терапия кандидурии // Клиническая микробиология и антимикробная химиотерапия. 2001. Т. 3, № 1. С. 22–27. EDN: VXFOSP

[89] Beloborodov VB, Sinyakova LA. Nosocomial candiduria: algorithm of diagnosis and treatment. Consilium medicum. 2003;5(7):380–384. (In Russ). EDN: UDFXAH

[90] Белобородов В.Б., Синякова Л.А. Нозокомиальная кандидурия: алгоритм диагностики и лечения // Consilium medicum. 2003. Т. 5, № 7. С. 380–384. EDN: UDFXAH

[91] Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis. 2000;30(4):662–678. doi: 10.1086/313749

[92] Rex J.H., Walsh T.J., Sobel J.D., et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis. 2000. Vol. 30, N 4. P. 662–678. doi: 10.1086/313749

[93] Kauffman CA. Diagnosis and management of fungal urinary tract infection. Infect Dis Clin North Am. 2014;(28):61–74. doi: 10.1016/j.idc.2013.09.004

[94] Kauffman C.A. Diagnosis and management of fungal urinary tract infection // Infect Dis Clin North Am. 2014. Vol. 28, N 1. P. 61–74. doi: 10.1016/j.idc.2013.09.004

[95] Achkar JM, Fries BC. Candida infections of the genitourinary tract. Clin Microbiol Rev. 2010;23(2):253–273. doi: 10.1128/CMR.00076-09

[96] Achkar J.M., Fries B.C. Candida infections of the genitourinary tract // Clin Microbiol Rev. 2010. Vol. 23, N 2. P. 253–273. doi: 10.1128/CMR.00076-09

[97] Sherry L, Murray C, Ramage G. Carbohydrate derived fulvic acid (CHD-FA) is a novel antifungal product: category: scientific free paper. Journal of Infection. 2011;63(6):e99. doi: 10.1016/j.jinf.2011.04.168

[98] Sherry L., Murray C., Ramage G. Carbohydrate derived fulvic acid (CHD-FA) is a novel antifungal product: category: scientific free paper // Journal of Infection. 2011. Vol. 63, N 6. P. e99. doi: 10.1016/j.jinf.2011.04.168

[99] Patent US 6569900B1. Dekker J, Medlen CE. Fulvic acid and its use in the treatment of candida infections. United States, 2003. Available from: https://patents.google.com/patent/US6569900B1/en

[100] Patent US 6569900B1. Dekker J., Medlen C.E. Fulvic acid and its use in the treatment of candida infections. United States, 2003. Режим доступа: https://patents.google.com/patent/US6569900B1/en

[101] Nivetha M, Sujatha S. Phytochemical analysis, antibacterial, antifungal and antiinflammatory activity of humic acid. International Journal of Research and Analytical Reviews. 2019;6(1):853–858.

[102] Nivetha M., Sujatha S. Phytochemical analysis, antibacterial, antifungal and antiinflammatory activity of humic acid // International Journal of Research and Analytical Reviews. 2019. Vol. 6, N 1. P. 853–858.

[103] Sherry L, Jose A, Murray C, et al. Carbohydrate derived fulvic acid: an in vitro investigation of a novel membrane active antiseptic agent against Candida albicans biofilms. Front Microbiol. 2012;3:116. doi: 10.3389/fmicb.2012.00116

[104] Sherry L., Jose A., Murray C., et al. Carbohydrate derived fulvic acid: an in vitro investigation of a novel membrane active antiseptic agent against Candida albicans biofilms // Front Microbiol. 2012. Vol. 3. P. 116. doi: 10.3389/fmicb.2012.00116

[105] Antoni S, Ferlay J, Soerjomataram I, et al. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71(1):96–108. doi: 10.1016/j.eururo.2016.06.010

[106] Antoni S., Ferlay J., Soerjomataram I., et al. Bladder cancer incidence and mortality: a global overview and recent trends // Eur Urol. 2017. Vol. 71, N 1. P. 96–108. doi: 10.1016/j.eururo.2016.06.010

[107] Wang L, Lu B, He M, et al. Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019. Front Public Health. 2022;10:811044. doi: 10.3389/fpubh.2022.811044

[108] Wang L., Lu B., He M., et al. Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019 // Front Public Health. 2022. Vol. 10. P. 811044. doi: 10.3389/fpubh.2022.811044

[109] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660

[110] Sung H., Ferlay J., Siegel R.L., et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries // CA Cancer J Clin. 2021. Vol. 71, N 3. P. 209–249. doi: 10.3322/caac.21660

[111] Şekerler T, Mısırlı D, Özsavcı D, et al. Paradoxical role of humic acid in some of cancer cell lines. Febs Journal. 2016;283(1):416. doi: 10.1111/febs.13808-416

[112] Şekerler T., Mısırlı D., Özsavcı D., et al. Paradoxical role of humic acid in some of cancer cell lines // Febs Journal. 2016. Vol. 283, N 1. P. 416. doi: 10.1111/febs.13808-416

[113] Jayasooriya RGPT, Dilshara MG, Kang CH, et al. Fulvic acid promotes extracellular anti-cancer mediators from RAW 264.7 cells, causing to cancer cell death in vitro. Int Immunopharmacol. 2016;36:241–248. doi: 10.1016/j.intimp.2016.04.029

[114] Jayasooriya R.G.P.T., Dilshara M.G., Kang C.H., et al. Fulvic acid promotes extracellular anti-cancer mediators from RAW 264.7 cells, causing to cancer cell death in vitro // Int Immunopharmacol. 2016. Vol. 36. P. 241–248. doi: 10.1016/j.intimp.2016.04.029

[115] Aydin SK, Dalgic S, Karaman M, et al. Effects of fulvic acid on different cancer cell lines. Proceedings. 2017;1(10):1031. doi: 10.3390/proceedings1101031

[116] Aydin S.K., Dalgic S., Karaman M., et al. Effects of fulvic acid on different cancer cell lines // Proceedings. 2017. Vol. 1, N 10. P. 1031. doi: 10.3390/proceedings1101031

[117] Kloskowski T, Szeliski K, Krzeszowiak K, et al. Mumio (Shilajit) as a potential chemotherapeutic for the urinary bladder cancer treatment. Sci Rep. 2021;11(1):22614. doi: 10.1038/s41598-021-01996-8

[118] Kloskowski T., Szeliski K., Krzeszowiak K., et al. Mumio (Shilajit) as a potential chemotherapeutic for the urinary bladder cancer treatment // Sci Rep. 2021. Vol. 11, N 1. P. 22614. doi: 10.1038/s41598-021-01996-8

[119] Schepetkin IA, Khlebnikov AI, Ah SY, et al. Characterization and biological activities of humic substances from mumie. J Agric Food Chem. 2003;51(18):5245–5254. doi: 10.1021/jf021101e

[120] Schepetkin I.A., Khlebnikov A.I., Ah S.Y., et al. Characterization and biological activities of humic substances from mumie // J Agric Food Chem. 2003. Vol. 51, N 18. P. 5245–5254. doi: 10.1021/jf021101e

[121] Brüne B. Nitric oxide: NO apoptosis or turning it ON? Cell Death Differ. 2003;10(8):864–869. doi: 10.1038/sj.cdd.4401261

[122] Brüne B. Nitric oxide: NO apoptosis or turning it ON? // Cell Death Differ. 2003. Vol. 10, N 8. P. 864–869. doi: 10.1038/sj.cdd.4401261

[123] Hseu YC, Huang HW, Wang SY, et al. Humic acid induces apoptosis in human endothelial cells. Toxicol Appl Pharmacol. 2002;182(1):34–43. doi: 10.1006/taap.2002.9429

[124] Hseu Y.C., Huang H.W., Wang S.Y., et al. Humic acid induces apoptosis in human endothelial cells // Toxicol Appl Pharmacol. 2002. Vol. 182, N 1. P. 34–43. doi: 10.1006/taap.2002.9429

[125] Salehi M, Piri H, Farasat A, et al. Activation of apoptosis and G0/G1 cell cycle arrest along with inhibition of melanogenesis by humic acid and fulvic acid: BAX/BCL-2 and Tyr genes expression and evaluation of nanomechanical properties in A375 human melanoma cell line. Iran J Basic Med Sci. 2022;25(4):489–496. doi: 10.22038/IJBMS.2022.60651.13444

[126] Salehi M., Piri H., Farasat A., et al. Activation of apoptosis and G0/G1 cell cycle arrest along with inhibition of melanogenesis by humic acid and fulvic acid: BAX/BCL-2 and Tyr genes expression and evaluation of nanomechanical properties in A375 human melanoma cell line // Iran J Basic Med Sci. 2022. Vol. 25, N 4. P. 489–496. doi: 10.22038/IJBMS.2022.60651.13444

[127] Pant K, Gupta P, Damania P, et al. Mineral pitch induces apoptosis and inhibits proliferation via modulating reactive oxygen species in hepatic cancer cells. BMC Complement Altern Med. 2016;16:148. doi: 10.1186/s12906-016-1131-z

[128] Pant K., Gupta P., Damania P., et al. Mineral pitch induces apoptosis and inhibits proliferation via modulating reactive oxygen species in hepatic cancer cells // BMC Complement Altern Med. 2016. Vol. 16. P. 148. doi: 10.1186/s12906-016-1131-z

[129] Dubishchev AV, Zaitceva EN, Makarenko NV. The mechanism of action of humic acids on excretory function of kidneys in norm and at the gentamycin nephropathy. Ukraїns’kij bіofarmacevtichnij zhurnal. 2014;(5):13–15. EDN: THZAYT

[130] Дубищев А.В., Зайцева Е.Н., Макаренко Н.В. Механизм действия гуминовых кислот на выделительную функцию почек в норме и при гентамициновой нефропатии // Український біофармацевтичний журнал. 2014. № 5. С. 13–15. EDN: THZAYT

[131] Slobodyan EI, Kaladze NN, Govdalyuk AL, Kulik EI. The nephroprotective potential of peloid therapy used for the rehabilitation of the patients presenting with chronic pyelonephritis. Problems of Balneology, Physiotherapy, and Exercise Therapy. 2017;94(3):62–68. EDN: ZFHVGF doi: 10.17116/kurort201794362-68

[132] Слободян Е.И., Каладзе Н.Н., Говдалюк А.Л., Кулик Е.И. Нефропротективный потенциал пелоидотерапии в реабилитации больных хроническим пиелонефритом // Вопросы курортологии, физиотерапии и лечебной физической культуры. 2017. Т. 94, № 3. С. 62–68. EDN: ZFHVGF doi: 10.17116/kurort201794362-68

[133] Menshih LE, Dubishchev AV. Humic acids as the factor of protection against gentamycin nephrotoxical action. Izvestiya Samarskogo nauchnogo centra Rossijskoj akademii nauk. 2011; 13(1-8):2021–2025. EDN: PUPFYP

[134] Меньших Л.Е., Дубищев А.В. Гуминовые кислоты как фактор защиты от нефротоксического действия гентамицина // Известия Самарского научного центра Российской академии наук. 2011. Т. 13, № 1-8. С. 2021–2025. EDN: PUPFYP

[135] Dubishchev AV, Menshih LE. Research of influence the humin substances of peloids on excretory function of nephros. Izvestiya Samarskogo nauchnogo centra Rossijskoj akademii nauk. 2010; 12(1-8):2023–2026. EDN: NDYHED

[136] Дубищев А.В., Меньших Л.Е. Исследование влияния гуминовых веществ пелоидов на экскреторную функцию почек // Известия Самарского научного центра Российской академии наук. 2010. Т. 12, № 1-8. С. 2023–2026. EDN: NDYHED

[137] Makarenko N, Zajceva E, Dubishchev A, Andriyanov D. The study of acute toxicity and diuretic activity of metal derivatives of humic, fulvic, and humus acids. Izvestiya Samarskogo nauchnogo centra Rossijskoj akademii nauk. 2015;17(5-3):925–929. EDN: WFCBDV

[138] Макаренко Н.В., Зайцева Е.Н., Дубищев А.В., Андриянов Д.А. Исследование острой токсичности и диуретической активности металлопроизводных гуминовых, фульвовых и гумусовых кислот // Известия Самарского научного центра Российской академии наук. 2015. Т. 17, № 5-3. С. 925–929. EDN: WFCBDV

[139] Makarenko N, Zajceva E, Dubishchev A. Analysis of the influence of magnesium, calcium and manganese fulvates on the excretory function of kidneys. Izvestiya Samarskogo nauchnogo centra Rossijskoj akademii nauk. 2015;17(2-2):273–278. EDN: UHUHKF

[140] Макаренко Н.В., Зайцева Е.Н., Дубищев А.В. Анализ влияния фульватов магния, кальция и марганца на экскреторную функцию почек // Известия Самарского научного центра Российской академии наук. 2015. Т. 17, № 2-2. С. 273–278. EDN: UHUHKF

[141] Akbas A, Silan C, Gulpinar MT, et al. Renoprotective effect of humic acid on renal ischemia-reperfusion injury: an experimental study in rats. Inflammation. 2015;38(6):2042–2048. doi: 10.1007/s10753-015-0185-2

[142] Akbas A., Silan C., Gulpinar M.T., et al. Renoprotective effect of humic acid on renal ischemia-reperfusion injury: an experimental study in rats // Inflammation. 2015. Vol. 38, N 6. P. 2042–2048. doi: 10.1007/s10753-015-0185-2

RIGHTS & PERMISSIONS

Eco-Vector